The collaboration combines AI-based analysis tools with a next-generation sequencing system to support labs performing tumor and liquid biopsy testing.
SOPHiA Genetics and Complete Genomics announced a collaboration to integrate AI-powered cancer testing applications with a new sequencing platform, aiming to broaden access to precision oncology testing worldwide.
The partnership combines SOPHiA Genetics’ MSK-IMPACT and MSK-ACCESS applications powered by SOPHiA DDM with Complete Genomics’ DNBSEQ-T1+ sequencing platform. The integrated solution provides laboratories with a sample-to-report workflow for both liquid biopsy and solid tumor testing applications.
The MSK applications were developed in collaboration with Memorial Sloan Kettering Cancer Center and are designed to run on SOPHiA Genetics’ AI-driven analytics platform. Complete Genomics’ DNBSEQ-T1+ platform delivers Q40-level accuracy with throughput ranging from 500 million to 2 billion reads per flow cell.
“Pairing MSK-IMPACT and MSK-ACCESS powered with SOPHiA DDM with our DNBSEQ-T1+ platform creates a powerful and accessible solution for laboratories looking to scale high-quality cancer genomic profiling,” says Rob Tarbox, vice president of product and marketing at Complete Genomics, in a release.
Platform Performance and Capacity
The DNBSEQ-T1+ platform features independent flow cell operation with 24-hour paired-end 150bp run times. At maximum throughput, each flow cell can process up to 60 tumor-normal sample pairs for tissue testing or up to 16 tumor-normal sample pairs for liquid biopsy applications.
Joint evaluation of the MSK applications on the DNBSEQ-T1+ platform demonstrated concordant variant calls and allele frequencies compared with equivalent sequencing systems, while achieving lower background noise and reduced turnaround time, according to the companies, according to a release from SOPHiA Genetics.
SOPHiA DDM is a technology-agnostic analytics platform that uses AI to compute, standardize, and analyze healthcare data. The platform showed seamless compatibility with existing SOPHiA DDM workflows during testing.
“This collaboration underscores SOPHiA Genetics’ commitment to broadening access to data-driven medicine,” says Ross Muken, president at SOPHiA Genetics, in a release. “Partnering with Complete Genomics to streamline use of MSK-IMPACT and MSK-ACCESS powered with SOPHiA DDM on the DNBSEQ-T1+ platform enables more laboratories around the world to adopt precision oncology through scalable, end-to-end genomic solutions.”
ID 385806354 | Ai Lab © BiancoBlue | Dreamstime.com
